Skip to main content
CTOR
NASDAQ Life Sciences

Major Shareholder's Stake Diluted to 71% Due to Recent Capital Raises

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.796
Mkt Cap
$74.004M
52W Low
$0.491
52W High
$6.19
52W Position info
62% above low
Off High info
87% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CTOR sits 62% above its 52-week low of $0.491 on light trading volume (0.1× avg).

Summary

Citius Pharmaceuticals, a major shareholder, reported a decrease in its stake in Citius Oncology to 71% due to the company's recent share issuances for capital raises.


Key Events · Ownership and Investor Activity · CTOR

  • Beneficial Ownership Decreased

    Citius Pharmaceuticals, Inc.'s stake in Citius Oncology decreased from 74.9% to 71.0% of outstanding common stock.

  • Dilution Confirmed

    The decrease in ownership is attributed solely to Citius Oncology's issuance of new shares, not to any sales by Citius Pharmaceuticals.

  • Reflects Recent Capital Raises

    This amendment updates the ownership percentage following Citius Oncology's recent capital raises and increased outstanding share count, as previously disclosed in other filings.


Analysis · CTOR · Life Sciences

Citius Pharmaceuticals, Inc.'s beneficial ownership in Citius Oncology has decreased from 74.9% to 71.0%. This reduction is solely due to Citius Oncology's recent issuance of new shares to raise capital, not from any sales by Citius Pharmaceuticals. This filing formally updates the ownership percentage, reflecting the significant dilution experienced by existing shareholders as the company secures financing amidst its going concern challenges.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 29.1% of the 1703 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CTOR was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74M. The 52-week trading range was $0.49 to $6.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTOR - Latest Insights

CTOR
Aug 14, 2026, 5:22 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.8399
Real-time Price: $1.05 info
Change: +$0.2101 (+25%) info
Market Cap: $97.63M info
CTOR
Aug 14, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8862
Real-time Price: $1.05 info
Change: +$0.1638 (+18%) info
Market Cap: $97.63M info
CTOR
Aug 14, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8862
Real-time Price: $1.05 info
Change: +$0.1638 (+18%) info
Market Cap: $97.63M info
CTOR
Aug 05, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $1.05 info
Change: +$0.392 (+60%) info
Market Cap: $97.63M info
CTOR
Aug 05, 2026, 9:17 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $0.6346
Real-time Price: $1.05 info
Change: +$0.4154 (+65%) info
Market Cap: $97.63M info